Imeik Technology Development Co.,Ltd.

XSEC:300896 Stock Report

Market Cap: CN¥43.8b

Imeik Technology DevelopmentLtd Valuation

Is 300896 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 300896 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 300896 (CN¥145.24) is trading below our estimate of future cash flow value (CN¥170.87)

Significantly Below Future Cash Flow Value: 300896 is trading below future cash flow value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300896?

Key metric: As 300896 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 300896. This is calculated by dividing 300896's market cap by their current earnings.
What is 300896's PE Ratio?
PE Ratio29.9x
EarningsCN¥1.47b
Market CapCN¥43.78b

Price to Earnings Ratio vs Peers

How does 300896's PE Ratio compare to its peers?

The above table shows the PE ratio for 300896 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average32.6x
002252 Shanghai RAAS Blood Products
22.6x13.59%CN¥41.2b
688336 Sunshine Guojian Pharmaceutical (Shanghai)
41.8x-32.22%CN¥36.3b
600161 Beijing Tiantan Biological Products
24.5x20.52%CN¥32.2b
603087 Gan & Lee Pharmaceuticals
41.8x28.97%CN¥38.7b
300896 Imeik Technology DevelopmentLtd
29.9x17.84%CN¥43.8b

Price-To-Earnings vs Peers: 300896 is good value based on its Price-To-Earnings Ratio (29.9x) compared to the peer average (32.6x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does 300896's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
300896 29.9xIndustry Avg. 47.6xNo. of Companies6PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 300896 is good value based on its Price-To-Earnings Ratio (29.9x) compared to the CN Biotechs industry average (47.6x).

Price to Earnings Ratio vs Fair Ratio

What is 300896's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300896 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio29.9x
Fair PE Ratio32.5x

Price-To-Earnings vs Fair Ratio: 300896 is good value based on its Price-To-Earnings Ratio (29.9x) compared to the estimated Fair Price-To-Earnings Ratio (32.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 300896 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
CN¥186.16
0%
14.82%CN¥228.00CN¥130.00n/a9
Feb ’27CN¥139.73
CN¥193.75
+38.66%
17.90%CN¥262.00CN¥130.00n/a10
Jan ’27CN¥141.72
CN¥194.75
+37.42%
16.91%CN¥262.00CN¥140.00n/a10
Dec ’26CN¥146.00
CN¥201.89
+38.28%
22.26%CN¥299.47CN¥140.00n/a10
Nov ’26CN¥160.09
CN¥201.89
+26.11%
22.26%CN¥299.47CN¥140.00n/a10
Oct ’26CN¥181.55
CN¥218.16
+20.17%
16.78%CN¥299.47CN¥160.00n/a10
Sep ’26CN¥196.90
CN¥216.99
+10.21%
17.33%CN¥299.47CN¥160.00n/a10
Aug ’26CN¥184.53
CN¥224.50
+21.66%
16.19%CN¥299.47CN¥176.00n/a10
Jul ’26CN¥173.30
CN¥224.50
+29.54%
16.19%CN¥299.47CN¥176.00n/a10
Jun ’26CN¥170.00
CN¥224.50
+32.06%
16.19%CN¥299.47CN¥176.00n/a10
May ’26CN¥173.00
CN¥225.90
+30.58%
15.35%CN¥299.47CN¥180.00n/a10
Apr ’26CN¥178.89
CN¥237.00
+32.48%
13.10%CN¥299.47CN¥188.00n/a10
Mar ’26CN¥169.86
CN¥265.90
+56.54%
27.45%CN¥472.14CN¥190.00n/a11
Feb ’26CN¥170.02
CN¥266.90
+56.98%
26.98%CN¥472.14CN¥201.00CN¥139.7311
Jan ’26CN¥182.50
CN¥266.90
+46.25%
26.98%CN¥472.14CN¥201.00CN¥141.7211
Dec ’25CN¥211.90
CN¥267.63
+26.30%
26.71%CN¥472.14CN¥201.00CN¥146.0011
Nov ’25CN¥211.02
CN¥268.23
+27.11%
26.76%CN¥472.14CN¥201.00CN¥160.0912
Oct ’25CN¥235.60
CN¥264.39
+12.22%
28.96%CN¥472.14CN¥180.00CN¥181.5512
Sep ’25CN¥144.96
CN¥282.99
+95.22%
31.76%CN¥478.07CN¥180.00CN¥196.9013
Aug ’25CN¥172.98
CN¥312.90
+80.89%
25.96%CN¥478.07CN¥207.00CN¥184.5313
Jul ’25CN¥173.66
CN¥307.52
+77.08%
22.04%CN¥478.07CN¥228.57CN¥173.3012
Jun ’25CN¥201.13
CN¥307.52
+52.90%
22.04%CN¥478.07CN¥228.57CN¥170.0012
May ’25CN¥214.80
CN¥315.86
+47.05%
21.01%CN¥478.07CN¥228.57CN¥173.0012
Apr ’25CN¥249.94
CN¥324.60
+29.87%
19.54%CN¥478.07CN¥269.29CN¥178.8911
Mar ’25CN¥229.44
CN¥326.35
+42.24%
24.85%CN¥478.07CN¥221.43CN¥169.8611
Feb ’25CN¥201.70
CN¥338.17
+67.66%
25.15%CN¥478.07CN¥221.43CN¥170.0211
CN¥186.16
Fair Value
22.0% undervalued intrinsic discount
9
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/21 12:20
End of Day Share Price 2026/02/13 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Imeik Technology Development Co.,Ltd. is covered by 28 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ethan CuiBofA Global Research
Pei ChengChina Galaxy Securities Co., Ltd.
Manqi HuangChina International Capital Corporation Limited